Medically reviewed by Yasmine S. Ali, MD, MSCI Key Takeaways Ejection fraction (EF) measures how well the heart pumps blood.A ...

Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...

A device you might want with you in an avalanche; why heart failure with preserved ejection fraction may be seen as a ...

By Karen Roman Biopharmaceutical company Medera Inc. said it completed patient enrollment for Cohort B of its clinical trial ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

Presenter: Christopher Fellows, MD, Virginia Mason Medical Center (Seattle, Washington) on behalf of the PAVE Study Group: LV based Cardiac Stimulation Post AV Nodal Ablation E valuation The ...

According to a recent study, in heart failure with reduced ejection fraction (HFrEF) patients, elevated high-sensitivity ...

Epicardial adipose tissue was associated with greater cardiac injury among patients who experienced an acute myocardial ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...